HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

B?亨特（Natasha B. Hunter）、拉内尔?M?彼得森（Lanell M. Peterson）等人，在《Breast Cancer Research》期刊上发表了题为 “Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2positive or HER2 - ...

This discovery, published in ACS Central Science, marks a turning point in the fight against estrogen receptor-positive (ER+) breast cancer, which accounts for 70 to 80% of cases. While current ...

There were no deaths in the placebo arm. ER+/HER2− breast cancer accounts for 70% of the around 2.3 million cases of breast cancer diagnosed worldwide in 2020. Prof Loi adds while these patients ...

6, 2025 (HealthDay News) -- For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding ...